Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

Amelia Evoli Stampanoni-B

Research output: Contribution to journalArticle

53 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology